Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price gapped down prior to trading on Friday . The stock had previously closed at $10.06, but opened at $9.73. Capricor Therapeutics shares last traded at $10.03, with a volume of 641,008 shares trading hands.

Key Stories Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Analyst upgrade provides support. Oppenheimer raised Capricor to Outperform, while another report cited an analyst upgrade as the catalyst for a sharp advance in the shares. The rating suggests the analyst sees potential upside after the stock’s substantial pullback from its 52-week high. Capricor Therapeutics Raised to Outperform at Oppenheimer
• Neutral Sentiment: Rejected shareholder vote narrows Capricor’s strategic options. A rejected vote is pushing the company toward a more limited path, which could affect its financing, corporate strategy, or development plans. The article did not establish whether the outcome creates an immediate financial impact. A Rejected Vote Pushes Capricor Toward a Narrower Path
• Negative Sentiment: Multiple law firms are promoting an investor securities class action. The lawsuit covers investors who purchased CAPR securities from December 17, 2025, through July 26, 2026. Allegations include misleading statements or omissions concerning the HOPE-3 trial’s pre-specified statistical analysis plan and FDA compliance. Investors have until September 28, 2026, to seek lead-plaintiff status; the allegations have not been proven. Capricor Securities Class Action Deadline Notice
• Negative Sentiment: Recent operating disclosures add to uncertainty. Investor-rights firms highlighted Capricor’s second-quarter earnings release and conference call, including the lack of a management question-and-answer session with analysts. Separately, the company’s latest reported quarterly EPS missed consensus expectations, reinforcing concerns about execution and cash needs while its pipeline advances. Capricor Q2 Earnings and Securities Class Action Update

Analysts Set New Price Targets

CAPR has been the topic of several analyst reports. LADENBURG THALM/SH SH cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Wall Street Zen cut Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. JonesTrading lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Finally, HC Wainwright restated a “neutral” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $29.15.

Capricor Therapeutics Trading Down 3.8%

The firm has a market capitalization of $562.80 million, a price-to-earnings ratio of -3.95 and a beta of 0.54. The company’s 50 day moving average is $14.83 and its 200-day moving average is $24.41.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Research analysts expect that Capricor Therapeutics, Inc. will post -1.72 EPS for the current year.

Insider Buying and Selling

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 25,000 shares of company stock worth $759,158 over the last three months. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new position in shares of Capricor Therapeutics in the first quarter valued at approximately $44,000. ACT Capital Management LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at $43,000. Allworth Financial LP grew its holdings in Capricor Therapeutics by 5,021.5% in the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 3,264 shares in the last quarter. State of Wyoming increased its position in Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after buying an additional 1,913 shares during the period. Finally, Royal Bank of Canada lifted its holdings in shares of Capricor Therapeutics by 12.4% during the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after buying an additional 557 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.